Gastrointestinal stromal tumor (GIST) is the most common mesenchymal malignancy of the digestive tract; approximately 70% originate from the stomach. It is thought that GISTs arise from the interstitial cells of Cajal. Extragastrointestinal stromal tumor (EGIST) is defined as a mesenchymal neoplasm arising from soft tissues outside the gastrointestinal tract, which is morphologically, histologically, and immunophenotypically similar to its gastrointestinal counterpart. Cajal-like cells have been described in the urinary tract and prostate, as well. Prostatic EGIST is rarely seen. It is defined as a mass in the prostate in radiologic imaging techniques. Diagnostic biopsy is essential in therapeutic approaches. The diagnosis of EGIST depends on the histopathologic features with immunohistochemical results. Indeed, immunohistochemistry has a major role in the differential diagnosis. Since their Cajal and/or Cajal-like cell origin, most of these tumors express KIT (CD117) tyrosine kinase and show the presence of activating mutations in KIT or platelet-derived growth factor receptor-α (1-3). Imatinib therapy alone or prostatectomy additional to imatinib therapy are the preferred methods for the treatment of prostatic EGIST. Here, we report a unique case of a primary EGIST of the prostate which was treated with enucleation without imatinib therapy and to our knowledge, resulted with the longest follow-up period.
CASE PRESENTATION
In 2010, a 56 year-old man presented with pain in the anal region. His medical history was unremarkable. A digital rectal examination revealed a markedly enlarged prostate with a smooth, bulging surface. The serum prostate-specific antigen (PSA) level was 1.1 ng/mL. Computerized tomography (CT) images showed a 6 cm heterogeneous, infiltrative tumor within the prostate gland extending to the trigon of the Figure 1 ). No lymph node involvement or any metastatic focus including bones was recorded. The colonoscopic examination revealed an extraluminal large asymmetric mass. The tru-cut biopsy of the prostate was reported as leiomyoma. At surgical observation, there were four seperate, circumscribed tumor masses located in the extraperitoneal, rectovesical and retroprostatic regions with no definitive association identified to the neighboring organs and structures. The masses were easily and completely removed from the adjacent structures. On macroscopic definition, the largest mass was measured 4 cm in diameter. The masses had well-defined borders with a pseudocapsule in shape and the cut surfaces were solid, firm and grayish-white. There were also some gritty areas in the macroscopic examination. Microscopic evaluation showed an infiltrative spindle cell proliferation with a mild cytologic atypia (Figure 2 per 50 high power fields (HPF) and there was no necrosis. The immunoprofile of the tumor was as follows: CD117 >50%: 3 (+), CD34 >50%: 1 (+), smooth muscle actin (SMA) <10% 1 (+), S-100 (-), desmin (-), Ki67 1% ( Figure 5 ). The case was reported as EGIST within the intermediate-risk category with free surgical margins. A close follow-up was planned with CT scan for every three months in the first year and later for every 6 months. Because of the intermediate risk of the tumor, and the legislations regarding drug prescription rules in our contry, imatinib was not prescribed as a synchronous treatment. The patient was problem-free for the rest 49 months. While there was no significant finding in April 2014, eight months later, in November, the CT scan showed multiple nodules, with a greatest dimension of 3.5 cm -showing irregular contours with extraprostatic extension. Additionally, severe nodal involvement, including the left obturatory and right inguinal area, was reported. On positron emission tomography, both asymmetric masses in the right prostate lobe and lymph nodes showed high metabolic activity. Serum PSA level was 3.91 ng/mL. A fixed mass was palpated on the right lobe on digital rectal examination. The tru-cut biopsy of prostate had a spindle cell tumor consistent with EGIST. The immunostaining results were almost the same as the first specimen: SMA (+), CD117 (+) (1+) 100%, CD34 diffuse (+) 100%, smoothelin (-) some isolated cells, α-methylacyl coenzyme A racemase (-), Keratin AE1/AE3 mildly-focal (+), S100 (-), estrogen and progesterone receptor (-), desmin focal (+). Ki67 proliferation index was 1%.
Mitotic figures were noted as 1/50 HPF. There was no necrosis. While two quadrants had 98% tumor, one had only 5% tumor. Because of the prostatic recurrence with nodal involvement, imatinib (Glivec; Novartis, Stein, Swiss) therapy was planned as a neoadjuvant therapy before radical surgery. A control CT showed regression in the tumoral masses in the 6 th month of follow-up and the patient has remained uneventful. Written informed consent has been obtained from the patient.
DISCUSSION
GISTs almost exclusively occur in the gastrointestinal tract. The combination of c-kit and CD34 has become the most reliable marker for the diagnosis. EGIST constitutes 5-10% of GIST with a mean age of 58 years and the majority of locations emerge from the mesentery, omentum, and retroperitoneum (3-7). Noteworthy, various cases have also been validated in other sites, including the pancreas, urinary bladder, and seminal vesicles (8) (9) (10) 
